Series: Landmark Trials in Endocrinology & Metabolism | Study #20
Category: Type 2 Diabetes · Glycaemic Control | Design: Multicentre, randomised controlled trial (within UKPDS) | n: 753 (metformin vs conventional); 951 (metformin vs sulphonylurea/insulin) | Follow-up: 10.7 years (median)
📋 Summary
Authors: UK Prospective Diabetes Study (UKPDS) Group
Journal: Lancet 1998;352:854–865 | PMID: 9742977
UKPDS 34 reported a pre-specified substudy within the UKPDS comparing the effects of metformin as intensive blood-glucose therapy in 1,704 overweight patients (greater than 120% ideal body weight) with newly diagnosed type 2 diabetes. Of these, 753 were included in a randomised comparison of conventional therapy primarily with diet (n=411) versus metformin-based intensive therapy targeting a fasting plasma glucose below 6 mmol/L (n=342), with a median follow-up of 10.7 years. A secondary analysis compared metformin-allocated patients with 951 overweight patients randomised to intensive therapy with sulphonylurea or insulin. Median HbA1c was 7.4% in the metformin group versus 8.0% in the conventional group. Metformin reduced the risk of any diabetes-related endpoint by 32% (95% CI 13 to 47%; p=0.002), diabetes-related death by 42% (9 to 63%; p=0.017), and all-cause mortality by 36% (9 to 55%; p=0.011). Compared with overweight patients on intensive therapy with sulphonylurea or insulin, metformin showed a significantly greater effect on any diabetes-related endpoint (p=0.0034), all-cause mortality (p=0.021), and stroke (p=0.032). The benefits of metformin were achieved with less weight gain and fewer hypoglycaemic episodes than with sulphonylurea or insulin.
📊 Key Findings
| Endpoint (metformin vs conventional) | Effect Size |
|---|---|
| Any diabetes-related endpoint | 32% reduction (13–47%) · p=0.002 |
| Diabetes-related death | 42% reduction (9–63%) · p=0.017 |
| All-cause mortality | 36% reduction (9–55%) · p=0.011 |
| Any MI | 39% reduction (11–59%) · p=0.01 |
| Advantage vs sulphonylurea/insulin (overweight) | Greater reduction in mortality, CV endpoints, stroke |
| Weight gain | Less than sulphonylurea or insulin |
| Hypoglycaemia | Lower than sulphonylurea or insulin |
💬 Expert Commentary
UKPDS 34 transformed metformin from a second-line alternative to the preferred first-line pharmacological therapy for overweight patients with newly diagnosed type 2 diabetes. The finding that metformin not only matched the glycaemic efficacy of sulphonylurea and insulin but produced better outcomes on diabetes-related endpoints, mortality, and myocardial infarction than comparably treated overweight patients on insulin or sulphonylurea was unexpected at the time and has generated debate ever since. Several hypotheses have been advanced to explain the mechanism: metformin’s glucose-lowering effect is achieved primarily through suppression of hepatic glucose production without stimulating insulin secretion, avoiding the hyperinsulinaemia hypothetically associated with accelerated atherogenesis in sulphonylurea- and insulin-treated patients; metformin may have direct anti-inflammatory and endothelial-protective effects mediated through AMPK activation; and the metabolic neutrality of metformin with respect to body weight may confer cardiovascular advantage over agents that promote weight gain.
The UKPDS 34 findings cemented metformin’s position as the standard first-line pharmacological therapy for type 2 diabetes in virtually every major international guideline for the subsequent three decades. Even as SGLT2 inhibitors and GLP-1 receptor agonists emerged with superior cardiovascular outcomes data in established cardiovascular disease populations, metformin has retained its first-line position in glucose-naive patients on the basis of UKPDS 34, its safety profile, weight neutrality, and cost. The concern raised by the supplementary analysis in UKPDS 34 about an increased risk of diabetes-related death when metformin was added to maximum sulphonylurea — a finding of HR 1.96 that generated considerable alarm at publication — was subsequently evaluated in additional analyses and not confirmed in multiple independent datasets, and is now considered likely to be a chance finding or the result of imbalanced baseline characteristics in the small subgroup studied.
Limitations: The metformin versus conventional comparison enrolled only 753 participants, giving relatively wide confidence intervals. The superior outcomes versus other intensive treatments were an observational comparison within a randomised framework and are subject to selection bias. The alarming sulphonylurea combination signal was not confirmed in subsequent studies. The study was funded by the UK MRC, BDA, and industry partners.
🔑 BOTTOM LINE
UKPDS 34 demonstrated that metformin reduces diabetes-related endpoints, diabetes-related death, and all-cause mortality by 32–42% in overweight newly diagnosed type 2 diabetes, with superior outcomes compared with sulphonylurea or insulin in overweight patients, establishing metformin as the preferred first-line pharmacological agent for type 2 diabetes — a position it has held in international guidelines for over 25 years.
⭐ Clinical Impact Rating: ●●●●● Practice-defining
